Pain from inflammation can and will likely affect all adults at some point in their lives, and for some, become chronic conditions that interfere with a normal quality of life.
During the first week of July 2018, five-hundred-and-thirty-five delegates from five continents met at the University of Leiden in the Netherlands for the 28th annual symposium of the International Cannabinoid Research Society (ICRS). The four-day conference showcased recent scientific discoveries about cannabis components and various ways of targeting the endocannabinoid system to improve health outcomes.
Many of our patients have called in asking about cannabinoid hyperemesis syndrome (CHS), as this syndrome has been reported in the media numerous times over the past few months. This is a very rare syndrome that occurs in long-term heavy users of THC-rich cannabis. CHS was first reported in the medical literature in 2004. Symptoms include nausea, vomiting and abdominal pain.
“David,” a 10 year old boy, had his first seizure at 2 months of age. The convulsions were photosensitive generalized tonic-clonic seizures that occurred 1-4 times each day. These events were occurring daily, even though he was being treated with two anti-seizure medications – lamotrigine (Lamictal) and valproic acid. But they had already tried carbamazepine, phenobarbital, zonisamide and levetiracetam (Keppra) without success.
Scientists at the University of Louisville School of Medicine in Kentucky have identified a previously unknown molecular target of cannabidiol (CBD), which may have significant therapeutic implications for Parkinson’s Disease (PD).
THCA (tetrahydrocannabinolic acid) is the non-psychoactive acid form of THC found in the plant when raw. THCA converts to THC when it is decarboxylated. Discover the clinical and laboratory research on THCA for epilepsy, chronic pain, digestive disorders, and more.
A cutting edge paper from three cannabis friendly medical professionals—Dustin Sulak, Russel Saneto, and Bonni Goldstein—outlines case reports and the applications of cannabis medicine for epilepsy and seizure disorders.
High Times article by Martin A Lee highlights the breakthrough research on CBD, and how it has revolutionized the story of cannabis medicine.
Low-dose and high-dose treatments, protocols for chronic users, and the potential benefits of psychoactivity.
Kevin McKernan on sequencing the cannabis genome and its implications for the cannabis industry and “personalized medicine.”